Peter Stein
Founder @ Norgine Ventures
Amsterdam, The Netherlands
Peter Stein is a venture - series unknown investor at Norgine Ventures in Amsterdam focused on Health Care and Medical Device. Peter Stein is the Chairman and Chief Executive and principal shareholder of Norgine, an independent, specialty pharmaceutical company with operations throughout Europe. In 2012 Peter founded Norgine Ventures. Prior to joining Norgine in 1987, Peter was a co-founder and Vice President of Invitron Corporation, a contract biomanufacturer formed as a spin-off from the Monsanto Company. He started his pharmaceutical career with Centocor. Peter holds BA and MA degrees in Chemistry from Harvard University and an MBA from Stanford University.
- Total investments:
- 14
- Last investment:
- Lead investor:
- 86%
Last updated:
For AI agents: llms.txt
Industries Peter Stein invests in
Stages Peter Stein invests in
Countries Peter Stein invests in
Contacts
| Type | Contact | Validation |
|---|---|---|
| Work email | ||
| Personal email | ||
| Work phone | ||
| Personal phone | ||
| Socials |
Investment Focus
Industry
- Health Care 11 (79%)
- Medical Device 10 (71%)
- Medical 6 (43%)
- Biotechnology 5 (36%)
- Manufacturing 4 (29%)
Stage
- Venture - Series Unknown 8 (57%)
- Debt Financing 3 (21%)
- Series B 2 (14%)
- Series A 1 (7%)
Country
- United Kingdom 4 (29%)
- The Netherlands 3 (21%)
- France 2 (14%)
- Spain 1 (7%)
- Denmark 1 (7%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
| Sirius Medical helps improve healthcare for cancer patients by developing medical devices that aid in surgical treatment. Their objective is to create intuitive and accurate gadgets that allow surgeons and radiologists to provide the finest treatment. Sirius Perception uses audio and visual feedback to provide real-time, directional advice forpinpointing tumors | $12.9M / Series B / Mar 21, 2023 | ||
| Impress – is European leading digital orthodontic DSO of new generationWe have a defensible model with the personal touch of an in-house orthodontist, true clinical expertise, and engaging directly with consumersImpress was founded in 2019 in Barcelona with the idea of combining the best of orthodontic tradition with the most innovativetechnology in the sector. From the very beginning the vision of the Impress founders was to introduce a different business model with a strong focus on medical experience and digitalization. The company is transforming the oral healthcare industry by developing its own chain of orthodontic clinics, which are characterized by their disruptive design and modern patient experience. The founders decided to build a medical company with the personal touch of in-house orthodontists, face-to-face care, and unique clinical expertise, where the proper implementation of business processes and digitalization are at the core.In less than 2 years, Impress has managed to position itself as the European leader in the orthodontic sector, has treated more than 22.000 smiles and already has a presence in more than 80 European cities. Its innovation and quality have earned it recognition from Sifted as one of the fastest growing HealthTech companies in Europe in 2020. | $125M / Series B / Jul 11, 2022 | ||
| The perfect package for any general surgical trainee or resident. Progress from beginner to advanced surgical techniques with Pyxus. The only take home simulator that includes lap appendectomy and cholecystectomy training models. | $7M / Venture - Series Unknown / May 17, 2022 | ||
| Alesi Surgical was founded in 2009 to develop and commercialise products that improve the safety, efficacy and outcomes of surgical procedures. The company is a spin-out from the Welsh Institute for Minimal Access Therapy (WIMAT), a leading surgical training centre in the UK. Alesi Surgical has a unique level of access to experiencedsurgeons, surgical trainers and trainees, which allows it to identify issues in procedures and design devices to address these issues. | $12.8M / Venture - Series Unknown / Jul 20, 2021 | ||
| Caresyntax is a digital surgery platform that enables OR teams to predict and improve surgical performance. Its enterprise-grade digital surgery platform delivers insights to improve patient outcomes by using proprietary software and AI to analyze large volumes of video, audio, images, device data, clinical, and operational data in and around theOR.Caresyntax insights help surgeons benchmark and improve their care, hospital administrators use surgical resources more efficiently, medical device companies advance better products, and insurance companies understand risk and devise more tailored policies. The software is used in more than 4,000 operating rooms worldwide, has supported more than 30,000 surgeons, and improved care for more than 2 million patients. | $11.9M / Series A / Sep 26, 2017 | ||
| EBS Technologies is a medical device company that has developed a stimulation system for the treatment of neurologically caused impairments such as visual field loss. Such impairments can be the result of stroke, traumatic-brain-injury, glaucoma or several other diseases.The EBS Therapy (previously: NEXT WAVE™Therapy) is a non-invasive opticnerve stimulation deploying weak electrical currents, resulting in neuroregeneration and neuroprotection. Low-voltage electrical pulses are administered at frequencies and amplitudes identified as optimal for each patient, allowing retinal ganglion cells to regenerate and branch out new axons. The company benefits from more than 15 years of research and clinical experience with more than 1,200 patients. Double blind, randomized studies, as well as clinical observations show that the EBS Therapy can partially restore vision field in patients.In 2013 EBS Technologies received the CE Mark for the stimulation device and started the commercial treatment in 2014. There are currently 8 EBS Treatment centers across Germany and the company is slowly widening the network. | $3.5M / Venture - Series Unknown / Aug 09, 2017 | ||
| PulseCath is a medical device company, develops, manufactures, and markets circulatory support systems to cardiologists and cardiac surgeons in the Netherlands and internationally. It offers iVAC 3L, a mid-range minimal heart circulatory assist device that generates up to three liters per minute, and offers critical hemodynamic support in the caseof left ventricular failure or during high-risk revascularization procedures with potential post cardiotomy weaning complications. | $3.3M / Venture - Series Unknown / Oct 10, 2016 | ||
| Q3 Medical Devices Limited is an Irish based holding company with multiple operations in Germany. The holding and its companies are focused on the development, manufacturing, and distribution of minimally invasive devices for the treatment of patients with cardiology, peripheral vascular and non-vascular diseases.Q3 Medical Devices Limited wasformed by a global group of entrepreneurs, manufactures, distributors, industry doctors, and investors focused on the development and acquisition of medical device businesses with annual revenues between 1 -10 Million. The acquisitions are targeted in areas that expand the groups manufacturing base and capabilities, growth of its distribution channels, and accelerating its products offering focused on the minimally invasive treatment of patients with cardiology, peripheral vascular and non-vascular diseases. | $5.6M / Venture - Series Unknown / Jun 21, 2016 | ||
| SpineVision is a spinal technology company focused on the development and marketing of implants and instrumentation for spinal treatment. The company offers spinal systems addressing a wide range of spinal pathologies including degenerative disc disease, deformity, cervical disorders, trauma and tumors. These products have been developed incollaboration with leading neurological and orthopedic surgeons which has resulted in over 20 patents.SpineVision was founded in 1999 and is headquartered in Antony in France, with subsidiaries in Belgium, Italy, the United Kingdom, and the United States. | $5M / Venture - Series Unknown / Nov 03, 2014 | ||
| Azanta is markets and distributes pharmaceutical products. Its products include Amnisure, Cicatridina, Repadina Plus, Cystistat, Flexi-T, Methadone, Oxandrin, Suplasyn, and development products. | $8.9M / Venture - Series Unknown / Oct 13, 2014 | ||
| See all 14 investments → | |||
Co-Investors
About Norgine Ventures
Norgine Ventures was started in 2012 to diversify Norgine’s activities and foster innovation in the healthcare sector. Norgine Ventures provides debt and debt-like financing to innovative, fast-growing companies in the fields of healthcare and life sciences, in Europe and the US. Norgine Ventures is backed by Norgine, a fully integrated, private, European healthcare company with over 110 years of experience in the pharma space. Norgine Ventures has full access to Norgine’s technical capabilities for evaluating investment opportunities, although the business is aimed at achieving a financial return rather than funding opportunities of strategic interest to Norgine. To date, Norgine Ventures has invested in a number of businesses, including specialty pharma, diagnostic and medical device companies, at various stages of their life cycle, both in Europe and in the US.
Norgine Ventures Contacts
| Name | Phone | Socials | |
|---|---|---|---|
|
Jörg Plessl
Director EU Affiliates, Regulatory Affairs at Germany
|
|||
Julien Michaux
Managing Director
|
|||
Moritz Reuter
Investment Associate
|
|||
|
Juán Alcántara
CEO
|
|||
|
Peter Stein
Founder
|
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar stage
Recommended lists
FAQ
What does Peter Stein invest in?
Peter Stein invests primarily in Health Care, Medical Device and Medical startups, most often at Venture - Series Unknown and Debt Financing stage. Most of the 14 investments tracked by Shizune back companies in United Kingdom. The Investment Focus section breaks down every industry, stage and country in the portfolio.
How do I contact Peter Stein?
Public channels for Peter Stein include LinkedIn. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
When did Peter Stein last invest?
The most recent investment recorded for Peter Stein closed in Mar 2023. Shizune tracks 14 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Nov 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
